# Saroglitazar Magnesium 4 mg for Nonalcoholic Fatty Liver Disease (NAFLD) in People Living With HIV in the US

> **NCT05211284** · PHASE2 · TERMINATED · sponsor: **Zydus Therapeutics Inc.** · enrollment: 4 (actual)

## Conditions studied

- Nonalcoholic Fatty Liver Disease

## Interventions

- **DRUG:** Saroglitazar Magnesium 4 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05211284
- **Lead sponsor:** Zydus Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-12-08
- **Primary completion:** 2023-10-02
- **Final completion:** 2023-10-02
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2025-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05211284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05211284, "Saroglitazar Magnesium 4 mg for Nonalcoholic Fatty Liver Disease (NAFLD) in People Living With HIV in the US". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05211284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*